Skip to content
DataLookout
Menu

XRPMSNCT04876781

Korean Post-marketing Surveillance for Xeljanz XR

StatusCompleted
PhaseNot specified
SponsorPfizer
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 26 versions: 10 with changes below, 16 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 15 words Show 4 more changesShow less
    • Trial completed
    • Primary and study completion dates changed from estimate of Sep 22, 2026 to Oct 20, 2026
    • Secondary endpoints: details revised at 2 of 5 entries
    • Site details revised
  2. Minor Primary and study completion pushed from Jun 30, 2026 to Sep 22, 2026v24
  3. Minor Primary and study completion dates: Dec 6, 2026 to Jun 30, 2026v20
  4. Notable Primary and study completion dates: Jun 30, 2024 to Dec 6, 2026v13
  5. Minor Primary and study completion dates: May 31, 2025 to Jun 30, 2024
    • Study description expanded, about 92 words
    v12
Show 4 earlier versionsHide 4 earlier versions
  1. Notable Eligibility criteria expanded, about 131 words
    • Primary endpoint revised
    • Secondary endpoints: 4 to 5
    v9
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Nov 1, 2021 to Jan 12, 2022
    v4
  3. Notable Eligibility criteria expanded, about 4 words
    • Secondary endpoints: 3 to 4
    v3
  4. Notable Start date: Jul 1, 2021 to Nov 1, 2021v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants With Treatment Emergent Adverse Events (AEs)
Timeframe: Maximum of 52 weeks from the time of initial administration of Xeljanz XR

Secondary (5)

Change from baseline in Disease Activity Score based on 28-joints Count (DAS28)
Percentage of Participants With European League Against Rheumatism (EULAR) Response Based on DAS28
Number of Participants With an American College of Rheumatology 20% (ACR20) Response
Assessment of Ankylosing Spondylitis response (ASAS20)
Changes from baseline in the number of tender joints and swollen joints

Arms and interventions

Drugs: Tofacitinib XR

Sites

1 site in 1 country

  • PfizerSeoul, South Korea